Reflections on the Sulphonylurea Story. A Drug Class at Risk of Extinction? Or A Drug Class Worth Reviving?

TY - JOUR

T1 - Reflections on the Sulphonylurea Story. A Drug Class at Risk of Extinction?

T2 - Or A Drug Class Worth Reviving?

AU - Cordiner, Ruth L. M.

AU - Pearson, Ewan R.

N1 - Wellcome Trust. Grant Number: 102820/Z/13/Z.

PY - 2019/2/11

Y1 - 2019/2/11

N2 - The role of sulphonylureas (SUs) in modern clinical practice poses ongoing clinical debate. With the advent of newer agents in diabetes management, there is an increasing shift away from the prescribing of SUs, but not necessarily to more effective agents. This review provides a different perspective on the debate, reflecting in depth upon the physiology of SUs, drawing on insights gained from monogenic diabetes to highlight the potential benefit of lower doses of SUs, and the probable benefit of gliclazide over most other, if not all SUs, in terms of sulphonylurea failure and cardiovascular outcomes.

AB - The role of sulphonylureas (SUs) in modern clinical practice poses ongoing clinical debate. With the advent of newer agents in diabetes management, there is an increasing shift away from the prescribing of SUs, but not necessarily to more effective agents. This review provides a different perspective on the debate, reflecting in depth upon the physiology of SUs, drawing on insights gained from monogenic diabetes to highlight the potential benefit of lower doses of SUs, and the probable benefit of gliclazide over most other, if not all SUs, in terms of sulphonylurea failure and cardiovascular outcomes.

KW - cardiovascular disease

KW - dose-response relationship

KW - glucose metabolism

KW - pharmacogenetics

KW - sulphonylureas

KW - type 2 diabetes

U2 - 10.1111/dom.13596

DO - 10.1111/dom.13596

M3 - Review article

C2 - 30471177

SN - 1462-8902

VL - 21

SP - 761

EP - 771

JO - Diabetes, Obesity & Metabolism

JF - Diabetes, Obesity & Metabolism

IS - 4

ER -